Steps To Consider To Reduce Risk Of Biopharma Component Shortages
By Paul Priebe
The supply chain woes resulting from the COVID-19 pandemic have highlighted the risks of supply interruptions across all industries and products. Ensuring adequate supply chain of components used in medical devices and in vitro diagnostic devices or components used for the manufacture of drugs and biologics is more challenging and more critical than ever.
Overall, implementing a supply risk mitigation strategy and partnering with the right component vendor are key actions in improving your own supply chain resiliency and maintaining your market position. Find out what steps you can take to reduce the risk of component shortages in medical devices and for the manufacture of drugs and biologics, and their consequences.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.